Clinical Trials
73 trialsNCT06064097 2026-05-27
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06050252 2026-05-22
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06770582 2026-05-22
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01585805 2026-05-19
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06029270 2026-05-19
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03606967 2026-05-13
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04164082 2026-05-13
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04310007 2026-05-13
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05211323 2026-05-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07504588 2026-05-13
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT02101775 2026-04-13
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02595892 2026-04-13
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02567409 2025-03-03
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01064622 2024-11-19
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020345 2023-10-31
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00026104 2020-10-30
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114179 2020-10-30
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00924209 2018-11-30
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01935947 2018-07-27
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01195415 2017-08-07
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075504 2015-09-28
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00337194 2015-02-23
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114244 2015-01-14
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00577889 2014-07-25
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093496 2014-05-20
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091026 2014-05-15
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027703 2014-02-11
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00024271 2014-01-06
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003780 2013-12-19
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003797 2013-12-19
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00027989 2013-12-18
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005958 2013-12-04
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003664 2013-11-06
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00064064 2013-11-06
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052689 2013-10-08
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00838656 2013-09-17
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01100372 2013-08-26
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00335543 2013-08-12
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00398385 2013-08-12
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00462852 2013-08-12
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01222676 2013-08-12
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00064051 2013-08-02
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096070 2013-07-16
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00028860 2013-07-10
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed